Overview
Updated 12 days agoHimalaya Nutravedics India Limited is an Ayurvedic and nutraceutical products manufacturer based in Hyderabad, Telangana. The company is transitioning from a B2B-focused model to an integrated B2B and direct-to-consumer (D2C) business model.
The red bar is the price band. GMP-implied price is an unofficial grey-market number, not a forecast.
How much to apply
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 1,200 | ₹1,27,200 |
| bNII (min) | 8 | 9,600 | ₹10,17,600 |
At the upper band. The amount is blocked in your bank account through UPI, not paid, until allotment.
Final subscription
As of 31 Oct, 16:42 ISTTimes the shares on offer were bid for, by investor category. Above 1x means the category is fully booked.
Listing performance
Latest price updated 5 hr ago.
Issue details
| Status | Listed |
| Exchange | BSE |
| Segment | SME |
| Price band | ₹100–106 |
| Final issue price | ₹106.00 |
| Face value | ₹10 per share |
| Lot size | 1,200 shares |
| Minimum investment | ₹1,27,200 |
| Issue size | ₹26.00 Cr |
| P/E at upper band | 8.8x |
| Registrar | KFIN TECHNOLOGIES LIMITED |
| NSE symbol | HNIL |
| ISIN | INE1OTR01013 |
Company & business
Himalaya Nutravedics India Limited operates a single integrated manufacturing facility in Hyderabad, Telangana, which is WHO-GMP compliant and holds various certifications including ISO 9001:2015, ISO 22000:2018, HACCP, HALAL, and KOSHER. The company manufactures a diverse portfolio of Ayurvedic and nutraceutical products, including capsules, tablets, liquid orals, and medicated oils, across therapeutic areas such as pain management, infertility, women's wellness, and gut health. Historically operating as a B2B entity, the company is now expanding into the direct-to-consumer (D2C) segment through e-commerce marketplaces, quick commerce platforms, and its own website. The company's operations are supported by a multi-tier distribution network spanning 17 states in India.
Objects of the issue — how the money will be used
- Funding Working Capital Requirements (₹13.75 Cr)
- Investment in Branding, Digital Marketing and Sales Expansion (₹7.5 Cr)
- General Corporate Purposes
Key strengths
- Experienced promoters and management team
- End-to-end in-house execution capabilities
- Long-term relationships with clients
- Strong quality assurance and control processes
- WHO-GMP compliant manufacturing facility
Key risks
- Trademark opposition proceedings pending for corporate logo and wordmark
- High revenue concentration from top customers
- Significant dependence on top 10 suppliers
- Geographical concentration of manufacturing operations in a single facility
- Expiry of tax benefits under Section 80-IAC after FY 2027
- Historical delays in statutory filings with the Registrar of Companies
- Dependence on leased premises for registered office and factory
Promoters
Rohit Asawa, Sneha Penmatsa, Divya Asawa
Decoded from the RHP with AI on 01-Nov-2026. Check the offer document before you apply.
Financials (restated, ₹ crore)
| Period | Revenue | Expenses | Profit after tax | Assets | Net worth | Borrowings |
|---|---|---|---|---|---|---|
| FY24 | 14.43 | -- | 0.43 | 6.09 | 1.34 | 3.23 |
| FY25 | 21.00 | -- | 2.23 | 10.82 | 6.75 | 1.76 |
| FY26 | 43.07 | -- | 7.39 | 24.42 | 16.38 | 5.13 |
Key performance indicators · FY26
Peers & valuation
Listed peers as chosen by the issuer in the offer document (Basis for Issue Price).
| Company | Revenue (₹ Cr) | EPS (₹) | P/E | RoNW % | NAV (₹) |
|---|---|---|---|---|---|
| Himalaya Nutravedics India this issue | 43.1 | 12.05 | 8.8x | 45.12 | 26.70 |
| Jeena Sikho Lifecare Limited | 801.4 | 17.84 | 28.8 | 27.67 | 37.60 |
| Sandu Pharmaceuticals Limited | 69.9 | 1.83 | 20.6 | 2.53 | 45.21 |
This issue is priced at 8.8x P/E against a peer median of 24.7x: a discount of 64%. A measurement, not a verdict.
Documents and resources
Offer documents and the issuer, exchange, registrar and SEBI pages for this issue.